Is It Too Late to Buy iBio Stock?

Stocks of coronavirus vaccine developers garnered investors' attention due to their potential to decisively end the COVID-19 pandemic and allow economies to return to normal via mass immunization. Right now, there are nearly 50 experimental SARS-CoV-2 vaccines in clinical trials and 89 vaccine candidates still in preclinical studies. The COVID-19 vaccine race is coming to an end, as the U.S. Food and Drug Administration (FDA) may issue emergency use authorization to one or more promising late-stage candidates as early as November.